Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies (COTI) has developed Phase 1 oral formulation candidates for COTI-2, a potentially first-in-class non-ATP competitive modulator/inhibitor of AKT/AKT2.
Subscribe to our email newsletter
The development of an oral formulation for use in humans aims to maximize the amount of an orally administered drug that is absorbed and then circulates in the body.
The formulation project will select the best candidate from the group based upon a number of criteria including ease in manufacturing, efficacy and pharmacokinetic profile, including bioavailability.
Studies involving two rodent species have demonstrated that orally administered COTI-2 can be developed as an out-patient cancer therapy taken daily or even on alternate days.
COTI CEO and president Wayne Danter said their evaluation of many potential formulations and test results has allowed them to identify eight oral formulation candidates.
COTI’s proprietary artificial intelligence system, Chemsas, utilizes a series of predictive computer models to identify compounds to be incorporated in disease-specific drug discovery, as well as optimization and preclinical development.